Two seasoned life sciences leaders join to accelerate business development, strategic partnerships, and AI-enabled clinical innovation.
WHEELING, IL, UNITED STATES, June 17, 2026 /EINPresswire.com/ — Luminari CRO, a full-service contract research organization supporting biotechnology, pharmaceutical, and life sciences companies, today announced the appointments of Dr. Anna Rodecki and Jeffrey Scott Yablon to its business development and strategic advisory team. The additions reflect Luminari CRO’s continued investment in growth and its commitment to helping life sciences organizations accelerate clinical development, improve operational efficiency, and leverage AI-enabled clinical and regulatory intelligence.
Dr. Anna Rodecki brings nearly two decades of experience helping life sciences organizations translate scientific innovation into clinical and commercial success. Her expertise spans clinical development, operations leadership, and strategic business development across a range of therapeutic areas. She has worked with global pharmaceutical companies, emerging biotechs, and CROs throughout her career.
Jeffrey Scott Yablon joins with extensive experience in business strategy, partnership development, and commercialization within the life sciences sector. He brings a track record of building relationships with pharmaceutical and biotech companies and translating those relationships into strategic growth opportunities.
AI-Enabled Clinical Innovation
Both appointments align with Luminari CRO’s broader strategy to integrate artificial intelligence into clinical operations and regulatory processes. The company is investing in AI-enabled tools that improve clinical trial design, accelerate regulatory submissions, and enhance patient recruitment and retention strategies.
Luminari CRO provides a comprehensive range of CRO services including clinical trial management, regulatory affairs consulting, biostatistics and data management, and medical monitoring. The company serves clients across oncology, neurology, rare diseases, and other therapeutic areas.
